Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,273
  • Shares Outstanding, K 16,712
  • Annual Sales, $ 0 K
  • Annual Income, $ -92,290 K
  • 60-Month Beta 1.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.18
Trade TNXP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.60
  • Number of Estimates 2
  • High Estimate -1.60
  • Low Estimate -1.60
  • Prior Year -2.24
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.91 +23.04%
on 05/18/22
5.22 -54.95%
on 04/26/22
-2.71 (-53.55%)
since 04/22/22
3-Month
1.91 +23.04%
on 05/18/22
11.52 -79.60%
on 03/03/22
-3.10 (-56.85%)
since 02/23/22
52-Week
1.91 +23.04%
on 05/18/22
45.44 -94.83%
on 06/08/21
-33.81 (-93.50%)
since 05/21/21

Most Recent Stories

More News
Why Tonix Pharmaceuticals Continued to Plummet Today

A spot of potentially good news can't stop the investor exodus from the biotech stock.

TNXP : 2.35 (-7.48%)
Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2

Tonix Exercises Option to License Antiviral Technology Platform...

TNXP : 2.35 (-7.48%)
Why Tonix Pharmaceuticals Stock Is Crashing Again Today

The sell-off that began on Monday continues.

TNXP : 2.35 (-7.48%)
Why Tonix Pharmaceuticals Stock Dived by Over 31% Today

You'd plummet to the ground too if you declared a major reverse stock split.

TNXP : 2.35 (-7.48%)
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split

CHATHAM, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...

TNXP : 2.35 (-7.48%)
Why Tonix Pharmaceuticals Got Crushed Today

Now is not a great time for pre-revenue biotechs to be reporting earnings.

TNXP : 2.35 (-7.48%)
Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Fibromyalgia Phase 3 Trial of TNX-102 SL Enrollment Initiated; Results from Interim Analysis Expected First Quarter 2023 Long COVID IND Cleared for...

TNXP : 2.35 (-7.48%)
Tonix Pharmaceuticals to Present at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

CHATHAM, N.J., April 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company,...

TNXP : 2.35 (-7.48%)
Tonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID Patients

Over 40% of Long COVID Patients Had Fibromyalgia-Like Multi-Site Pain Symptoms Rate of Opioid Use in Long COVID Patients with Multi-Site Pain is a...

TNXP : 2.35 (-7.48%)
Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)

Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Expected to Start Second Quarter 2022 Long COVID Afflicts More Than 30% of Patients...

TNXP : 2.35 (-7.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 3.49
2nd Resistance Point 3.21
1st Resistance Point 2.78
Last Price 2.35
1st Support Level 2.07
2nd Support Level 1.79
3rd Support Level 1.36

See More

52-Week High 45.44
Fibonacci 61.8% 28.81
Fibonacci 50% 23.67
Fibonacci 38.2% 18.54
Last Price 2.35
52-Week Low 1.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar